drugset / Trial / NCT05031494
A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC)
Timeline
- Start
- 2021-12-08
- Primary completion
- 2023-08-16
- Completion
- 2023-08-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Nab-paclitaxel | Small molecule | — | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |
| Subject | YH003 | Unknown | — | — |